Success stories

Here we present just a few concrete examples to show Lenis’ competency in various segments of the distribution value chain: from regulatory to sales activities, from Early Access Programs (EAP) to product life cycle management.

Unlicensed medicines reimbursed and dispensed through pharmacies

Slovenia has regulatory mechanisms in place that enable essential unlicensed prescription medicines to be treated almost as if they were licensed. Lenis is the pioneer and now leading supplier of such medicines with over 30 unlicensed medicines reimbursed and dispensed through pharmacies.

Off-patent innovative hepatitis medicine

Before its patent expiry, this drug was the leading Hepatitis medication in Albania with over 500 patients treated. Since then, 4 generics came to the market with a low co-pay for patients. Still, about 200 patients have chosen to pay a higher co-pay, just to have access to this trusted innovative medicine.

Off-patent innovative HIV medicine

Following a long wait for reimbursement in Serbia, this innovative medicine was approved just months before two leading generic companies had their products reimbursed. Today, 7 years later, this off-patent innovative drug still commands 60% MS. The sales were over EUR 1 million in 2022.

Off-patent innovative epilepsy medicine

Physicians expressed a need for a steady supply of this older epilepsy drug that was sporadically available only in hospitals. Lenis approached the product owner and managed to obtain reimbursement for this off-patent unlicensed medicine so that it can now be dispensed in pharmacies. The regular supply enabled doctors to replace some less suitable therapies with this medicine. We sold around 4.000 packs in Slovenia within the first full year on the market, and started selling it to Serbia, as well.

Innovative epilepsy medicine

Lenis implemented the Early Patient Access program in 2022, obtained a higher than IRP approved price, performed local labelling, and arranged individual patient reimbursement as one of the first EU countries. The product owner recently asked Lenis to extend the EPA program to three additional countries.

Oromucosal epilepsy medicine

Based on the request of a KOL, Lenis started distributing this medicine 10 years ago as a reimbursed unlicensed Rx medicine in Slovenia even before it had marketing authorization in any country (“Special” status in UK). Due to successful market penetration the product owner decided to register the drug in Slovenia. Over the years, this product has become the standard of care with over 17.000 doses sold in 2022.

Generic injectable neurology medicine

As the only generic supplier, Lenis distributes 2 generic versions of this medicine to assure uninterrupted supply and to reduce the cost for hospitals. Over the years, we essentially displaced the originator from the market.

Off-patent innovative liposomal medicine

Lenis has managed for years to preserve this product’s value in Slovenia and, consequently, through the IRP system, in the region. This resulted in additional revenue for the principal.

Despite a less-than-perfect dossier, Lenis successfully completed product registrations in Serbia and Albania, leading to market exclusivity and a significant sales increase.

Innovative HIV medicine

Due to well-executed cross-functional efforts of our medical and marketing teams, this drug has become the leading HIV medicine in the region. Soon after the launch, following an early reimbursement, Slovenia has risen to the top 3 countries in the world in market share.

Generic nephrology medicine

Gastro-resistant capsules were launched as reimbursed unlicensed prescription medicine and soon completely replaced an immediate release medicine with the same active ingredient. It is now the standard of care for patients before and on dialysis, because it contributes to better disease management for patients, and saves the health insurance fund money. After reaching the agreed sales threshold, Lenis helped the principal to obtain marketing authorization and a favorable reimbursement price.

Off-patent UTI medicine

After the Slovenian Health Insurance Fund expressed interest, Lenis started supplying and obtained reimbursement for this unlicensed medicine more than 10 years ago.

The market potential then was estimated by a leading specialist to be 10.000 packs per year. Since then, this product became the leading UTI medicine in Slovenia with over 60.000 packs sold in 2022. Over the years, Lenis managed to mitigate supply chain issues with a variety of regulatory and commercial tools.

As a local regulatory agent, Lenis helped the principal obtain marketing authorization through a shortened procedure (Cyprus clause). This is still the only Rx product in the country with an MA based on the Cyprus clause.